<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777190</url>
  </required_header>
  <id_info>
    <org_study_id>00005107</org_study_id>
    <nct_id>NCT02777190</nct_id>
  </id_info>
  <brief_title>A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor</brief_title>
  <official_title>A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study if misoprostol administered orally is at least as
      effective as misoprostol administered vaginally for cervical ripening and the induction of
      labor. The main purpose is to show that oral misoprostol administration is non-inferior to
      vaginal misoprostol administration with respect to the time interval from misoprostol
      administration to onset of active phase of labor. The study is a non-inferiority, prospective
      randomized controlled trial comparing oral misoprostol given as 25 mcg every 2 hours versus
      vaginal misoprostol given as 25 mcg every 4 hours.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time interval from start of induction of labor (first misoprostol administration) to active phase of labor (greater than or equal to 6 cm cervical dilation).</measure>
    <time_frame>12-24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time interval from start of induction of labor to initiation of oxytocin for augmentation</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time interval from start of induction of labor to vaginal delivery</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cesarean section rate</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of tachysystole</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of tachysystole causing non-reassuring fetal heart tones</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of need for tocolysis</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of chorioamnionitis</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of meconium stained fluid</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal morbidity</measure>
    <time_frame>1-2 days</time_frame>
    <description>composite outcome of Apgar score, cord gases, neonatal intensive care unit admission, and/or neonatal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of anti-emetic use</measure>
    <time_frame>1-2 days</time_frame>
    <description>maternal side effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of diarrhea</measure>
    <time_frame>1-2 days</time_frame>
    <description>maternal side effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of vaginal delivery within 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of abandoning misoprostol for cervical ripening and switching to mechanical dilation for cervical ripening</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of development of preeclampsia requiring magnesium sulfate administration</measure>
    <time_frame>12-24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment emergent serious adverse events</measure>
    <time_frame>0-28 days</time_frame>
    <description>uterine rupture, cesarean hysterectomy, maternal death during hospitalization, neonatal death (0-28 days of life) related to the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>1-2 days</time_frame>
    <description>postpartum hemorrhage requiring blood transfusion, maternal surgical ICU admission, neonatal NICU admission during mother's hospital admission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Labor; Forced or Induced, Affecting Fetus or Newborn</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Oral misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral misoprostol given 25 mcg every 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vaginal misoprostol given 25 mcg every 4 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.</description>
    <arm_group_label>Oral misoprostol</arm_group_label>
    <arm_group_label>Vaginal misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant Female Patients greater than or equal to 18 years of age

          2. Induction of labor for a single live intrauterine pregnancy

          3. Greater than or equal to 37 weeks gestational age

          4. Cephalic presentation

          5. 20 minute reassuring fetal heart rate (reactive nonstress test (NST))

          6. Bishop score based on sterile vaginal exam of less than or equal to 6, for which the
             cervical dilation is less than or equal to 2 cm.

          7. Equal to 3 or less uterine contractions over 10 minutes

        Exclusion Criteria:

          1. Previous uterine scar

          2. Contraindication to vaginal delivery

          3. Patients with preeclampsia

          4. Grand multiparty - greater than or equal to 5 live births or stillbirths

          5. Premature rupture of membranes

          6. Suspected intrauterine growth restriction

          7. Fetal anomalies

          8. Contraindication to misoprostol (history of allergy to prostaglandins, glaucoma)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaimey Pauli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Shoemaker, MD</last_name>
    <phone>717-531-8521</phone>
    <phone_ext>5855</phone_ext>
    <email>ashoemaker1@pennstatehealth.psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Eyer</last_name>
    <phone>717-531-6208</phone>
    <email>seyer@pennstatehealth.psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew D Shoemaker, MD</last_name>
      <phone>717-531-8521</phone>
      <phone_ext>5855</phone_ext>
      <email>ashoemaker1@pennstatehealth.psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jaimey Pauli, MD</last_name>
      <phone>7175318142</phone>
      <phone_ext>5</phone_ext>
      <email>jpauli@pennstatehealth.psu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Jaimey M. Pauli, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>misoprostol</keyword>
  <keyword>cytotec</keyword>
  <keyword>cervical ripening</keyword>
  <keyword>labor, induced</keyword>
  <keyword>active labor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

